Synapse - Works

Results (13087)

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: Updated result of a Phase 1b/2 study

Meeting Abstract

Matasar, M.; Herrera, A. F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T. M.; Kim, W. S.; Bosch, F.; Radford, J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Whole-body diffusion-weighted MR imaging in lymphoma surveillance

Meeting Abstract

Rademaker, J.; Ryan, D.; Matasar, M.; Portlock, C.
Hematological Oncology (2017)

Fulltext@MSK | Save

Interim data from the first clinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory Hodgkin/non-Hodgkin lymphoma

Meeting Abstract

Horwitz, S. M.; Fanale, M. A.; Spira, A. I.; Havenith, K.; He, S.; Feingold, J. M.; Hamadani, M.
Hematological Oncology (2017)

Fulltext@MSK | Save

Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell non-Hodgkin lymphoma: Phase I results from the T-cell consortium

Meeting Abstract

Lunning, M.; Horwitz, S.; Mehta-Shah, N.; Moskowitz, A.; Advani, R.; Beaven, A.; Haverkos, B.; Lechowicz, M.; Oki, Y.; Zain, J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Safety run-in of copanlisib in combination with rituximab plus bendamustine in patients with relapsed indolent non-Hodgkin's lymphoma

Meeting Abstract

Gerecitano, J.; Santoro, A.; Leppä, S.; Kim, T.; Kim, W.; Janssens, A.; Pedersen, M.; Reis, D.; Granvil, C.; Shen, J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

ME-401, a novel, oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ) in early clinical development for B-cell lymphoid malignancies

Meeting Abstract

Ghalie, R. G.; Pagel, J. M.; Soumerai, J.; Iasonos, A.; Patel, K.; Moreno, O.; Butler, T.; Zelenetz, A. D.
Hematological Oncology (2017)

Fulltext@MSK | Save

CheckMate 647: A Phase 2, open-label study of nivolumab in relapsed/refractory primary central nervous system lymphoma or relapsed/refractory primary testicular lymphoma

Meeting Abstract

Nayak, L.; Iwamoto, F. M.; Ferreri, A. J.; Santoro, A.; Singer, S.; Batlevi, C.; Batchelor, T.; Rubenstein, J.; Johnston, P.; Ramchandren, R.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era

Meeting Abstract

Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Meeting Abstract

Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma

Meeting Abstract

Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save